Nurix Therapeutics
(NASDAQ) NRIX
Nurix Therapeutics Financials at a Glance
Market Cap
$2.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$71.78M
Net Income (TTM)
-$295.28M
EPS (TTM)
-$3.16
P/E Ratio
-7.72
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$24.42
Volume
54,213
Open
$24.09
Price
$24.42
Volume
54,213
Open
$24.09
Previous Close
$24.42
Daily Range
$23.76 - $24.59
52-Week Range
$8.20 - $24.88
Estimated Earnings Date
Jul 9, 2026
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$24.42
Volume
54,213
Open
$24.09
Previous Close
$24.42
Daily Range
$23.76 - $24.59
52-Week Range
$8.20 - $24.88
Estimated Earnings Date
Jul 9, 2026
NRIX News
NRIX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Nurix Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
317
CEO
Arthur T. Sands, MD, PhD
Website
www.nurixtx.comHeadquarters
Brisbane, CA 94005, US
NRIX Financials
Key Financial Metrics (TTM)
Gross Margin
-139.43%
Operating Margin
-439.26%
Net Income Margin
-411.37%
Return on Equity
-64.21%
Return on Capital
-48.05%
Return on Assets
-46.42%
Earnings Yield
-12.95%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
103.41M
Volume
54.21K
Avg. Volume
1.97M
Financials (TTM)
Gross Profit
-$100.09M
Operating Income
-$315.30M
EBITDA
-$274.24M
Operating Cash Flow
-$260.29M
Capital Expenditure
-$11.56M
Free Cash Flow
-$271.85M
Cash & ST Invst.
$540.73M
Total Debt
$58.66M
Nurix Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$6.25M
-66.1%
Gross Profit
-$77.89M
-52.1%
Gross Margin
-12.46%
N/A
Market Cap
$2.52BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$8.04M
N/A
Employees
314
N/A
Net Income
-$87.17M
-54.7%
EBITDA
-$83.40M
-54.4%
Quarterly Fundamentals
Total Cash
$540.73M
-1.6%
Total Debt
$58.66M
+120.3%
Accounts Receivable
$2.40M
N/A
Inventory
$0.00
N/A
Long Term Debt
$55.45M
+177.5%
Short Term Debt
$3.20M
-51.8%
Return on Assets
-46.42%
N/A
Return on Invested Capital
-57.97%
N/A
Free Cash Flow
-$72.96M
-13.0%
Operating Cash Flow
-$71.91M
-17.7%